Express Pharma

IPM clocks Rs 6898 crores in October 2014

0 2

The Jharkhand market grew the highest, followed by Madhya Pradesh and Odisha

The Indian Pharma Market (IPM) has clocked Rs 6898 crores in October 2014. It has grown at 5.2 per cent in the said month. Amongst the top 10, GlaxoSmithKline Pharmaceuticals (GSK) grew by 12.8 per cent followed by Ranbaxy at 12.4 per cent and Mankind at 10.2 per cent. 27 corporate have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Akumentis has the highest growth of 66.1 per cent followed by Ajanta at 22.9 per cent and Merck at 22.4 per cent. 15 corporates have shown growths more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporates, Macleods has the highest growth of 22 per cent followed by USV at 16 per cent and Intas at 13.3 per cent. Amongst the 51-60 ranked corporates, Allergan has grown at 18 per cent followed by Troikaa at 13.3 per cent and Panacea at 12.5 per cent. Amongst the 61-75 ranked corporates, Boehringer grew by 59.5 per cent followed by East India at 14.5 per cent and Tablets India at 12.7 per cent.

Indian companies have grown at five per cent versus 5.7 per cent for MNCs in October 2014. Amongst the top 50 in MNCs, Merck grew by 22.4 per cent followed by GSK at 12.8 per cent and Ranbaxy at 12.4 per cent. Under the non-National List of Essential Medicines (NLEM) category Indian companies grew at 6.7 per cent whereas MNCs grew at 6.9 per cent.

With Bonus Units at Full Value
Val in Crs
Rank
MAT Oct -14
Oct-14
COMPANY
MAT
MTH
Val (Cr)
MS%
GR%
Val (Cr)
MS%
GR%
IPM
81103
100.00
9.6
6898
100.00
5.2
Sun Pharma
1
1
4373
5.39
14.4
376
5.46
8.5
Cipla
2
2
4069
5.02
11.2
349
5.06
9.5
Zydus Cadila
3
4
3175
3.91
7.6
262
3.80
1.6
Ranbaxy
4
3
2938
3.62
7.0
268
3.89
12.4
Mankind
5
5
2922
3.60
11.6
253
3.66
10.2
Glaxo
6
8
2761
3.40
-7.0
224
3.25
12.8
Lupin
7
7
2721
3.36
12.7
225
3.26
5.2
Abbott HC
8
9
2690
3.32
-0.5
218
3.15
-9.1
Alkem
9
6
2612
3.22
14.0
230
3.33
3.9
Pfizer
10
11
2367
2.92
8.1
201
2.92
9.8
Macleods
11
10
2316
2.86
23.9
203
2.94
22.0
Intas
12
12
2120
2.61
15.6
190
2.75
13.3
Aristo
13
13
2039
2.51
20.6
183
2.66
9.9
Sanofi India
14
14
1979
2.44
0.4
169
2.44
2.8
Torrent
15
16
1772
2.18
4.9
141
2.04
-5.1
Glenmark
16
15
1758
2.17
15.2
151
2.18
2.4
Dr. Reddys
17
17
1723
2.12
9.3
140
2.04
2.5
Abbott
18
19
1614
1.99
13.8
139
2.01
12.3
Micro Lab
19
21
1572
1.94
10.2
122
1.76
-9.5
USV
20
18
1562
1.93
16.0
139
2.02
16.0
Ipca
21
20
1469
1.81
23.0
128
1.86
0.7
Emcure
22
22
1405
1.73
20.0
116
1.67
3.2
Novartis
23
23
1150
1.42
0.0
100
1.45
5.8
Alembic
24
24
1108
1.37
13.1
95
1.38
5.2
Wockhardt
25
25
995
1.23
6.1
80
1.16
3.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The DPCO 2013 containing molecules market de-grew at -2.4 per cent whereas the non-DPCO market grew by 6.8 per cent resulting in an overall growth of 5.2 per cent for October 2014. NLEM and non-NLEM category showed negative unit growth at -5.7 per cent and -1.7 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 1.5 per cent, GSK 3.5 per cent, Ranbaxy 18.1 per cent.

From the therapy perspective, nine therapies have outgrown the IPM growth and five therapies have double digit growths. The respiratory market grew at 6.7 per cent, gastrointestinal market grew at 6.8 per cent, pain and analgesics market grew at 5.9 per cent whereas the anti-infectives grew at 3.3 per cent.

The anti-diabetic market grew at 13.5 per cent and the cardiac at 1.9 per cent in chronic business. The derma market grew by 10.3 per cent and the urology market at 21.1 per cent. From the regional perspective, 15 regions have outgrown the IPM growth. The Jharkhand market grew the highest at 20.4 per cent followed by the Madhya Pradesh market at 17.2 per cent and Odisha at 16.5 per cent. Five regions had negative growth in October 2014.

Amoxycillin + Clavulanic acid market grew at 5.9 per cent whereas Glimepiride + Metformin grew at 6.1 per cent at No 2.

Val in Crs
MAT Oct 14
Month Oct-14
Super Group
Val in Crs
Val GR%
Val in Crs
Val GR%
IPM
81103
9.6
6898
5.2
ANTI-INFECTIVES
13148
5.7
1153
3.3
CARDIAC
9994
9.0
821
1.9
GASTRO INTESTINAL
9309
11.0
769
6.8
VITAMINS / MINERALS / NUTRIENTS
7301
10.2
613
4.8
RESPIRATORY
6312
12.2
561
6.7
ANTI DIABETIC
6015
19.4
524
13.5
PAIN / ANALGESICS
5825
8.9
501
5.9
NEURO / CNS
5049
7.5
417
1.1
DERMA
4603
15.7
400
10.3
GYNAECOLOGICAL
4151
4.0
336
1.8
OPHTHAL / OTOLOGICALS
1478
12.5
132
17.0
HORMONES
1336
4.4
112
2.7
ANTI-NEOPLASTICS
1319
27.1
107
7.9
VACCINES
1144
-8.2
89
-6.2
BLOOD RELATED
973
2.2
76
-9.3
OTHERS
879
7.7
76
10.9
UROLOGY
834
18.6
76
21.1
ANTI MALARIALS
615
9.2
70
-0.8
SEX STIMULANTS / REJUVENATORS
454
2.4
35
-5.3
STOMATOLOGICALS
365
11.7
30
3.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The markets of paracetamol grew at 12.2 per cent, Atorvastatin 4.4 per cent, Azithromycin at 8.5 per cent, Probiotic Microbes at 20.6 per cent, Cefixime -5.9 per cent, Pantoprazole 5.7 per cent, Montelukast + Levocetrizine at 13 per cent, Glimepiride + Metformin + Pioglitazone at 17.2 per cent, Vitamin-D at 22.3 per cent, Hydroquinone + Mometasone + Tretinoin at 15 per cent, Voglibose + Metformin + Glimepiride at 39.2 per cent, Leveteracetam at 25.5 per cent.

Mixtard continues to lead the pack with Rs 29.5 crores for October 2014 with a growth of 12.2 per cent. Lantus grew at 26.8 per cent, Glycomet- GP grew at 25.2 per cent, Augmentin grew at 24.9 per cent, amongst the top 10 brands.

Amongst the brands who have gained ranks include Augmentin (+5), Glycomet-GP (+4), Lantus (+9), Dexorange (+6), Galvus Met (+12), Skinlite (+10), Spasmoproxyvon Plus ( +84), Pan (+11), Thyronorm (+19), Pan D ( +26), Jalra M (+48) amongst Top 100 Brands over October 2013.

Amongst the top brands in the IPM, Spasmoproxyvon Plus (116.9 per cent), Taxim (32.7 per cent), Galvus Met (31.6 per cent), Lantus (26.8 per cent), Glycomet – GP (25.2 per cent), Augmentin (24.9 per cent), PAN (24.2 per cent), Skinlite (22.6 per cent), grew fastest amongst the top 30 brands over October 2013.

A total of 167 brands were launched in October 2014.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocd.net

Leave A Reply

Your email address will not be published.